Does Lowering Heart Rate Improve Outcomes in Children With Dilated Cardiomyopathy and Chronic Heart Failure?

Lipshultz, Steven E.; Barach, Paul; Wilkinson, James D.

doi:10.1016/j.jacc.2017.07.749

Cited by 4 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The short-term results in some of the studies reviewed could be used to justify further exploration of these drugs for cardioprotection in patients with cancer. However, longer, adequately powered, welldesigned clinical trials with clinical endpoints, including comparative analysis with existing effective medications, such as dexrazoxane, are required [176].…”

Section: Discussionmentioning

confidence: 99%

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors

et al. 2019

Self Cite

View full text Add to dashboard Cite

Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can cause short-and long-term cardiotoxicity. The clinical implications of this cardiotoxicity become more important with the increasing use of cardiotoxic drugs. The implications are especially serious among patients predisposed to adverse cardiac effects, such as youth, the elderly, those with cardiovascular comorbidities, and those receiving additional chemotherapies or thoracic radiation. However, the optimal strategy for preventing and managing chemotherapyinduced cardiotoxicity remains unknown. The routine use of neurohormonal antagonists for cardioprotection is not currently justified, given the marginal benefits and associated adverse events, particularly with long-term use. The only United States Food and Drug Administration and European Medicines Agency approved treatment for preventing anthracycline-related cardiomyopathy is dexrazoxane. We advocate administering dexrazoxane during cancer treatment to limit the cardiotoxic effects of anthracycline chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%